Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine
In: International Journal of Hematology, Jg. 114 (2021-09-24), S. 544-553
Online
unknown
Zugriff:
Adoptive transfer of in vitro expanded, chimeric antigen receptor (CAR)-redirected CD19-specific T cells can induce dramatic disease regression in patients with leukemia and lymphomas. However, the full potential of this emerging modality is hampered in some cancer settings by a significant rate of therapeutic failure arising from the attenuated engraftment and persistence of CAR-redirected T cells, and tumor relapse following adoptive transfer. Here, we discuss an advanced strategy that facilitates post-infusion in vivo boosting of CAR T cells via CMV vaccination, to mediate durable remission of B cell malignancies by engrafting a CAR molecule onto a CMV-specific T cell. We also discuss a feasible and unique platform for the generation of the CMV-CD19CAR T cells for clinical application. This new approach would overcome multiple challenges in current CAR T cell technology including: short T cell persistence, limited duration of response, and inability to re-stimulate T cells after relapse or persistent disease.
Titel: |
Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine
|
---|---|
Autor/in / Beteiligte Person: | Diamond, Don J. ; Wang, Xiuli ; Forman, Stephen J. ; Nakamura, Ryotaro |
Link: | |
Zeitschrift: | International Journal of Hematology, Jg. 114 (2021-09-24), S. 544-553 |
Veröffentlichung: | Springer Science and Business Media LLC, 2021 |
Medientyp: | unknown |
ISSN: | 1865-3774 (print) ; 0925-5710 (print) |
DOI: | 10.1007/s12185-021-03215-6 |
Schlagwort: |
|
Sonstiges: |
|